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R
apid developments in genomic testing methods
have made the sequencing of a person’s DNA faster
and cheaper than ever before. The latest gene
sequencing machines can sequence all 20,000
human genes in less than 3 days at a cost of less
than $2000 per person. This is comparable to the cost of testing
just one gene using slightly older sequencing machines. 
But what are the scientific and ethical issues involved in the
use of genomic information as a “lifetime health resource”? Are
we ready for the wide application of genome testing in people
who are otherwise well?
Genomic Testing
Genomic testing has proven to be a powerful research tool, and
already has facilitated many major research breakthroughs,
particularly in the fields of cancer medicine and rare genetic
diseases. More recently, clinical genomic testing has emerged as
a component of individual health care, and a range of genomic
tests are now offered by public and commercial laboratories. 
Clinical genomic tests are already highly effective and cost-
efficient in the diagnosis of patients with rare or unusual presen-
tations. A recent study published in Genetics in Medicine by
the Melbourne Genomics Health Alliance
(http://tinyurl.com/z94bw7z) demonstrated that genomic
testing of previously undiagnosed children could identify a
diagnosis in approximately half of children tested, at a much
higher diagnosis rate and lower cost than traditional diagnostic
tests. In many cases the diagnosis led to significant changes to
the child’s treatment – such as a child experiencing seizures
being able to be treated with a vitamin. It also provided fami-
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If lives could be saved by being “forewarned” by a genomic test, should we perform genomic
testing of all babies at birth?
lies with valuable information and an ending to what for many
had been a prolonged “diagnostic odyssey”.
The success of genomic testing for the diagnosis of rare dis -
orders has in turn raised the question of whether these tests
should be undertaken in healthy people before they get sick.
The potential benefits of early diagnosis are obvious, particu-
larly for conditions for which prevention is possible. Further,
if lives could be saved by being forewarned by a genomic test,
why not perform genomic testing in all babies at birth?
Newborn Screening 
Newborn screening is, in fact, a well-established public health
endeavour in Australia and around the world. However, these
programs do not yet utilise genomic technology. In existing
newborn screening programs, parents give permission for some
blood to be taken from their baby’s heel soon after birth. This
sample is used to check for a selection of about 30 diseases for
which early identification or treatment is beneficial. 
One of the best examples of diseases screened is a metabolic
condition called phenylketonuria (PKU). Diagnosis of PKU will
enable parents to provide a tailored diet that prevents their
child from developing an intellectual disability. However, PKU
and other disorders tested by current newborn screening tests
represent just a fraction of the thousands of rare genetic disor-
ders that can affect children. Genomic sequencing provides the
opportunity to test for all of this with a single test. 
The potential benefits of genomic newborn screening are
clear. A baby identified as being at risk of sudden cardiac death
could be placed on protective medication that may save her
life. A baby born with a high risk of cancer could have extra
cancer screening tests to make sure that his cancer was detected
at an early stage. A baby born with a predisposition to a fatal drug
reaction could carry a warning bracelet to make sure she was
never given the drug. And in all of these situations there may
also be a health benefit to the baby’s parents and other rela-
tives who may unknowingly carry the same genetic risk.
Moreover, there is no need for the health benefits of genomic
sequencing to end in childhood. Genomic information can
provide a blueprint for individual health that is relevant through
all ages and stages of life. Therefore a test performed in a newborn
represents a potential lifetime health resource.
Should We Use Genomic Screening 
in All Newborns? 
The above individual examples make a strong case for genomic
testing of newborns. However, the huge resources required for
such a program also need to be considered. 
First and foremost, we must consider the financial cost. Even
if costs could be reduced to $1000 per genome sequence for
each baby tested, to test all 300,000 Australian babies born
each year would cost $300 million for the testing alone. When
the costs of counselling and interpretation of the huge amount
of information are added, the cost would be considerably higher.
In contrast, current newborn screening using biochemical tech-
niques costs just $20 per baby screened. 
Second, we must acknowledge that our ability to interpret
genomic information is in its infancy. Even for those whom
we know, with certainty, have a genetic condition, it can be
challenging to identify a specific disease-causing gene change.
A particular problem is that we all carry literally millions of
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these genetic variants. Of these, perhaps a handful might cause
disease but the remainder are harmless. Another problem is
that a particular variant may not always lead to disease in
everyone who has it.
Sorting out which variants we need to be worried about is
far from straightforward, particularly when the people being
tested are healthy newborns. Unfortunately, genomic testing is
not yet the precise tool that some might imagine it to be. 
Therefore genomic testing of all newborns would lead
inevitably to some healthy babies being incorrectly diagnosed
with a serious disorder, while other babies who did have a
genetic condition could have their diagnosis missed. We would
also have to work out how to manage and use this complex
information as the child grows up.
We therefore have two good reasons, huge financial costs
and difficulty interpreting results, that go some way to explaining
why genomic sequencing in not yet ready for use as a tool for
newborn screening. But what if these two obstacles could be
removed, as may possibly be the case in the future? Would there
still be other reasons to avoid genomic screening in newborns?
Ethics and the Lifetime Health Resource 
Common to debates about genetics are issues surrounding the
privacy and disclosure of genetic information, and the storage or
future use of test samples and data. However, Australia has good
legal and regulatory controls in place. So if it’s affordable, easier
to interpret and well-protected, do other ethical concerns arise? 
First, the way that consent to this test is obtained needs
further consideration. We know that parents already have poor
recall of newborn screening. It’s also widely recognised that
the standard ways of gaining consent to a health test are not
suitable for genomic testing. If the test is going to become more
complex we’ll need to engage parents in a way that promotes the
significance of the test and its future importance without nega-
tively impacting acceptance of existing screening methods. 
Second, in newborn testing it will be the child’s parents or
guardians who are providing this consent, but not all of the
information is going to be relevant in childhood. A well-estab-
lished principle in genetics is that genetic information not rele-
vant to childhood should not, in general, be disclosed until the
child in question is old enough to be part of the decision. 
We think this principle still has a strong foundation and
should not be routinely overridden for the sake of it being
convenient to obtain this information. This may mean that
certain information is not disclosed to parents, but is left for the
child to decide about later in life.
If we are to uphold this principle in genomic newborn
screening, it will add to the resource costs. But if we don’t
uphold this principle, we risk undermining the future autonomy
of the child who is tested.
Third, genetic information is shared within families, so infor-
mation obtained in genomic newborn screening may have rele-
vance for other family members too. While the prospect of
these benefits cascading out is important, this will also give rise
to issues over appropriate communication and possible further
counselling in these additional people.
Finally, alongside the significant hype about genomics, a
quieter discussion is taking place around the appropriate place
and use of genomic testing in medicine. Unfettered use of
genomic testing will likely lead to false positive and false nega-
tive results, or to overdiagnosis. Overdiagnosis occurs when a
diagnosis is “correct” but leads to harmful interventions or
labelling. As an example, for each baby who benefits from
increased cancer screening there will undoubtedly be many
others who undergo regular screening when they would never
have developed cancer. Because screening itself can carry risks,
these harms also need to be considered.
If we are to take seriously the point about appropriate use of
genomic technologies, we need to commit to using them when
they are likely to be effective and when the majority of ethical
concerns have been addressed. For this reason, mass popula-
tion screening programs of any kind tend to be led by a speci-
fied and important health care need, rather than a desire to use
a particular technology. Criteria for screening acceptability
from the World Health Organisation emphasise this along-
side other considerations such as the need for an intervention,
population acceptability and economic balance. 
We suggest that any decision about creating lifetime health
resources should only be done when we have a clear idea about
the benefits this may give rise to, with appropriate protections
in place for the custodianship and use of the information gained.
Engagement with Health 
While genomic testing has important potential to optimise
human health, we are not yet ready – medically or ethically –
to obtain the genomes of all newborns. If a lifetime health
resource is to come to fruition, we need to think more about
cost-effectiveness, custodianship of the data and engagement
with families over time. 
We have suggested some reasons why it’s still premature to
routinely sequence the genome of all newborns. This conclusion
was also reached by the Global Alliance for Genomics and Health,
which will soon release a set of recommendations on genomic
technologies in newborn screening. We need to think more about
the knowledge we’d gain and how it could be used in childhood
and beyond. In so doing, we should not ignore the interests of the
adults whom the children will eventually become. 
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